Addressing this enigma, our innovative approach included knocking down HER2 in HR+/HER2-low breast cancer cells, resulting in a substantial enhancement of the inhibitory effects exerted by the combination of CDK4/6 inhibitor and endocrine therapy. The gene discussed is ERBB2; the disease is breast carcinoma.